Biodexa shares surge 24.54% premarket after securing exclusive license for Otsuka’s Phase 1-ready GIST molecular glue.

Biodexa Pharmaceuticals Plc (BDRX) surged 24.54% in premarket trading following the announcement of an exclusive license for Otsuka’s OPB-171775, a Phase 1-ready molecular glue targeting gastrointestinal stromal tumors (GIST). The licensing agreement, disclosed 16 minutes prior, positions BDRX to advance a novel therapeutic candidate, potentially accelerating its pipeline development and attracting investor interest. While prior reports highlighted management changes and ADR price fluctuations, the immediate catalyst aligns with the stock’s sharp premarket rise.